Onivyde
Total Payments
$24.3M
Transactions
10,888
Doctors
4,372
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $8.3M | 5,916 | 3,234 |
| 2023 | $11.3M | 2,086 | 1,214 |
| 2020 | $43.72 | 2 | 2 |
| 2018 | $3.1M | 1,857 | 445 |
| 2017 | $1.6M | 1,027 | 459 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.1M | 1,121 | 86.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.7M | 504 | 7.0% |
| Consulting Fee | $519,178 | 182 | 2.1% |
| Travel and Lodging | $346,462 | 811 | 1.4% |
| Food and Beverage | $281,568 | 7,688 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $177,484 | 66 | 0.7% |
| Honoraria | $88,035 | 17 | 0.4% |
| Education | $74,920 | 499 | 0.3% |
Payments by Type
Research
$21.1M
1,121 transactions
General
$3.2M
9,767 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer | Ipsen Biopharmaceuticals, Inc | $2.1M | 0 |
| A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma | Ipsen Biopharmaceuticals, Inc | $1.8M | 0 |
| Total Neoadjuvant NALIRIFOX Plus Ablative Dose Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma | Ipsen Biopharmaceuticals, Inc | $1.7M | 0 |
| A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naive Metastatic Pancreatic Cancer (GIANT) | Ipsen Biopharmaceuticals, Inc | $1.5M | 0 |
| Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin | Ipsen Biopharmaceuticals, Inc | $1.4M | 0 |
| A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation with Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer | Ipsen Biopharmaceuticals, Inc | $1.2M | 0 |
| A Phase I Study in Patients Treated With MM-398 Nanoliposomal Irinotecan, Nal-IRI to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment | Ipsen Bioscience Inc | $1.2M | 0 |
| PHASE II STUDY OF NANOLIPOSOMAL IRINOTECAN WITH TAS102 AND BEVACIZUMAB FOR PATIENTS WITH METASTATIC COLORECTAL CANCER | Ipsen Biopharmaceuticals, Inc | $1.2M | 0 |
| An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | Ipsen Bioscience Inc. | $1.0M | 0 |
| A RANDOMIZED PHASE I/II STUDY OF ONIVYDE IN COMBINATION WITH TALAZOPARIB OR TEMOZOLOMIDE IN CHILDREN WITH RECURRENT SOLID MALIGNANCIES AND EWING SARCOMA | Ipsen Biopharmaceuticals, Inc | $1.0M | 0 |
| Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan and Immunotherapy (Plus Trastuzumab for HER2-positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma | Ipsen Biopharmaceuticals, Inc | $1.0M | 0 |
| Alternating neoadjuvant Gemcitabine-Nab-Paclitaxel and Nanoliposomal irinotecan with 5-Fluorouracil and folinic acid regimens in resectable and borderline resectable pancreatic cancer | Ipsen Biopharmaceuticals, Inc | $658,964 | 0 |
| A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan Nal-IRI-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma | Ipsen Bioscience Inc | $633,572 | 0 |
| A Phase II Study of Neoadjuvant NAPOX Followed by Chemoradiation With Paclitaxel and Carboplatin in Locally Advanced Esophagogastric Cancer | Ipsen Biopharmaceuticals, Inc | $621,878 | 0 |
| RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy | Ipsen Bioscience Inc. | $467,730 | 0 |
| Phase II_Preoperative Chemotherapy plus Ablative Dose Radiation in PDAC (v0.1) | Ipsen Biopharmaceuticals, Inc | $312,558 | 0 |
| A PROTOCOL FOR THE TREATMENT OF NEWLY DIAGNOSED RHABDOMYOSARCOMA USING MOLECULAR RISK STRATIFICATION AND LIPOSOMAL IRINOTECAN BASED THERAPY IN CHILDREN WITH INTERMEDIATE- AND HIGH-RISK DISEASE | Ipsen Biopharmaceuticals, Inc | $276,600 | 0 |
| A Phase II Study to Evaluate the Efficacy of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067 | Ipsen Biopharmaceuticals, Inc | $266,714 | 0 |
| A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) | Ipsen Biopharmaceuticals, Inc | $248,308 | 0 |
| A Phase I Study ofOnivydeand5-FUin Combination With Xilonix for Advanced Pancreatic Cancer WithCachexia | Ipsen Biopharmaceuticals, Inc | $218,827 | 0 |
Top Doctors Receiving Payments for Onivyde — Page 175
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Hematology & Oncology | Dalton, GA | $10.37 | 1 |
| , MD | Specialist | Atlanta, GA | $10.37 | 1 |
| , MD | Hematology & Oncology | Williamsburg, VA | $10.37 | 1 |
| , MD | Hematology & Oncology | Richmond, VA | $10.37 | 1 |
| Priya Jain | Internal Medicine | Kettering, OH | $10.37 | 1 |
| , M.D | Internal Medicine | Richmond, VA | $10.37 | 1 |
| , M.D | Hematology & Oncology | Spokane, WA | $10.37 | 1 |
| , MD | Medical Oncology | Elyria, OH | $10.37 | 1 |
| , MD | Hematology & Oncology | Marietta, OH | $10.37 | 1 |
| , M.D | Internal Medicine | Newport News, VA | $10.37 | 1 |
| , M.D | Hematology | Leesburg, FL | $9.90 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Mobile, AL | $9.46 | 2 |
| , MD | Medical Oncology | Mobile, AL | $9.46 | 2 |
| Mark Mainwaring | — | Murfreesboro, TN | $9.44 | 1 |
| , M.D | Hematology & Oncology | Chester, PA | $9.12 | 1 |
| , M.D | Specialist | Bakersfield, CA | $8.70 | 4 |
| , MD | Hematology & Oncology | Bakersfield, CA | $8.70 | 4 |
| , M.D | Hematology & Oncology | Birmingham, AL | $8.53 | 1 |
| , M.D | Neurology | Birmingham, AL | $8.53 | 1 |
| , M.D | Pediatrics | Houston, TX | $7.52 | 2 |
| , M.D | Specialist | Bakersfield, CA | $6.44 | 3 |
| , MD | Surgery | New York, NY | $1.65 | 2 |
| , M.D | Hematology & Oncology | Lake Worth, FL | $1.03 | 1 |
Ad
Manufacturing Companies
- Ipsen Biopharmaceuticals, Inc $20.6M
- Ipsen Bioscience Inc $2.2M
- Ipsen Bioscience Inc. $1.5M
- Epizyme, Inc. $947.09
Product Information
- Type Drug
- Total Payments $24.3M
- Total Doctors 4,372
- Transactions 10,888
About Onivyde
Onivyde is a drug associated with $24.3M in payments to 4,372 healthcare providers, recorded across 10,888 transactions in the CMS Open Payments database. The primary manufacturer is Ipsen Biopharmaceuticals, Inc.
Payment data is available from 2017 to 2024. In 2024, $8.3M was paid across 5,916 transactions to 3,234 doctors.
The most common payment nature for Onivyde is "Unspecified" ($21.1M, 86.9% of total).
Onivyde is associated with 20 research studies, including "NAPOLI-2: Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer" ($2.1M).